Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease
The use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has changed the clinical practice of dyslipidemia and their effects in cardiovascular events. Nowadays two active principles have been commercialized (evolocumab and alircumab) with indication in patients with low-density l...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-09-01
|
| Series: | Nefrología (English Edition) |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2013251420301279 |